Log in | Register

When antibiotic treatment fails

Matteo Bassetti| Josè Garnacho Montero| José Artur Paiva
Editorial
Volume 44, Issue 1 / January , 2018

Pages 73 - 75

No abstract available.

References

  1. Talbot GH (2014) The early response end point in clinical trials not just for FDA anymore? Infect Dis Clin Pract 22(6):307–308
    • View reference on publisher's website
  2. Sanchez Garcia M (2009) Early antibiotic failure. Int J Antimicrob Agents 34(S14):S19
  3. Timsit JF, de Kraker MEA, Sommer H, Weiss E, Bettiol E et al (2017) Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net. Intensive Care Med 43:1002–1012
  4. Luna CM, Blanzaco D, Niederman MS et al (2003) Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 31:676–682
    • View reference on publisher's website
    • View reference on PubMed
  5. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A (2017) Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. doi:10.1007/s00134-017-4878-x
  6. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H (2012) Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis 55:1114–1121
    • View reference on publisher's website
    • View reference on PubMed
  7. Joung MK, Lee JA et al (2011) Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 15(2):R79
    • View reference on publisher's website
    • View reference on PubMed
  8. Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A et al (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:32–40
  9. Seligman R, Meisner M, Lisboa TC et al (2006) Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 10:R125
    • View reference on publisher's website
    • View reference on PubMed
  10. Jensen JU, Hein L, Lundgren B et al (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39:2048–2058. doi:10.1097/CCM.0b013e31821e8791
    • View reference on publisher's website
    • View reference on PubMed
  11. Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos M et al (2008) Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 63:447–452
    • View reference on publisher's website
    • View reference on PubMed
  12. Gonçalves-Pereira J, Conceiçao C, Póvoa P (2013) Community-acquired pneumonia: identification and evaluation of nonresponders. Ther Adv Infect Dis 1(1):5–17
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement